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Abstract
Typhoid fever is common in developing countries, with an estimated 120 million infections and 700 000 annual deaths, worldwide.
Fluoroquinolones have been the treatment of choice for infection with multidrug-resistant (MDR) Salmonella enterica serovar Typhi
(S. Typhi). However, alarming reports of ﬂuoroquinolone-resistance and failure of typhoid fever treatment have recently been published. To
determine the proportion of S. Typhi isolates with reduced susceptibility to ciproﬂoxacin (RSC) from six countries in the Middle East and
Central Asia, 968 S. Typhi isolates collected between 2002 and 2007 from Egypt, Uzbekistan, Pakistan, Qatar, Jordan and Iraq were tested
for antibiotic susceptibility to ﬁve antibiotics using the disc-diffusion method. MDR was deﬁned as resistance to amicillin, chloramphenicol
and trimethoprim-sulfamethoxazole. The E-test was employed to determine the MIC of ciproﬂoxacin only. Nalidixic acid resistance was
evaluated as a marker for RSC. Interpretations were made according to CLSI guidelines. MDR strains were considerably more prevalent in
Iraq (83%) and Pakistan (52%) compared with the other countries studied (13–52%). Nearly all isolates were susceptible (99.7%) to
ceftriaxone. RSC was detected in a total of 218 isolates (22%), mostly from Iraq (54/59, 92%), Uzbekistan (98/123, 80%), Qatar (23/43, 54%)
and Pakistan (31/65, 47%). Many of these (21%) were also MDR. Use of nalidixic acid resistance as an indicator for RSC was 99% sensitive
and 98% speciﬁc. This study reinforces the need for routine antimicrobial susceptibility surveillance of enteric fever isolates and close review
of current therapeutic policies in the region.
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Introduction
Typhoid fever presents a major public health problem where
safe drinking water and sanitation are inadequate. Endemic
regions include developing countries in south-central and
South East Asia and many parts of Africa and Latin America [1].
The disease is caused by Salmonella enterica serovar Typhi
(S. Typhi). In Egypt, population-based studies have shown an
annual incidence of 13/100 000 persons in Belbis District in the
Nile Delta [2] and 61/100 000 persons in Fayoum Governor-
ate in the south [3]. Likewise, thousands of Iraqis are affected
each year, with 10–20% mortality rates due to limited access
to fresh water and dumping of sewage into the rivers [4].
Infection is also common in Jordan, but data and epidemio-
logical studies from the Ministry of Health are limited and
incidence is not well deﬁned because of the lack of efﬁcient
reporting systems [5]. In Pakistan, the incidence of typhoid
fever is comparatively high (451/100 000), supporting the
previous ﬁndings of Kothari et al. [6] who had claimed higher
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typhoid fever burden in Asia than Africa. Meanwhile, increasing
rates of typhoid fever have been detected in Uzbekistan due to
the deterioration of water treatment and distribution systems
in the republics of the former Soviet Union [7]. In Qatar, most
infections are imported from the endemic Indian sub-continent
and the Far East through expatriate workers and visitors [1].
In the past, S. Typhi infections were routinely treated with
chloramphenicol, ampicillin, or trimethoprim-sulfamethoxaz-
ole, but multidrug-resistance (MDR) to these antibiotics
started to emerge in 1990 [8]. In response, physicians in
endemic areas shifted to ﬂuoroquinolones or third-generation
cephalosporins to ensure better treatment outcomes [9,10].
Although this has resulted in a gradual return of strain
sensitivity to chloramphenicol [9,11,12], ﬂuoroquinolones are
often still preferentially used to achieve better recovery rates
[13].
Despite the recently reported susceptibility of S. Typhi
isolates to ciproﬂoxacin by the disc-diffusion method, patients
in many endemic areas have begun to present with clinical
treatment failures leading to serious consequences [14–16].
This treatment failure was observed for the ﬁrst time in India
in 1991 and subsequently recognized in other nearby coun-
tries. However, the minimum inhibitory concentrations (MICs)
of these isolates indicated reduced susceptibility to ciproﬂox-
acin (RSC) [14,17]. Since routine use of MIC methods is
expensive, resistance to nalidixic acid, the predecessor of the
quinolone family, has been used alternatively as an indirect
evidence of ﬂuoroquinolone resistance [14,16].
In this study, MDR resistance to ampicillin, chloramphenicol
and trimethoprim-sulfamethoxazole was determined for 968
S. Typhi isolates that were collected from the Middle East and
Central Asia between 2002 and 2007. Decreased susceptibility
to ﬂuoroquinolones was also evaluated for the ﬁrst time in
Egypt and neighbouring countries using standard ciproﬂoxacin
and nalidixic acid disc-diffusion tests.
Materials and Methods
Salmonella Typhi blood culture isolates collected during acute
febrile illness surveillance in Egypt and Uzbekistan were
archived at 70°C at the U.S. Naval Medical Research Unit
No. 3 (NAMRU-3) and used for the purposes of this study.
Isolates from other countries were recovered from stool or
blood cultures of patients during sporadic acute febrile illness
outbreaks in Iraq, Jordan, Pakistan and Qatar. Ethical approval
for all sample collection was obtained from the institutional
review boards of NAMRU-3 and the respective authorities in
the collaborating countries. All study subjects provided written
informed consent for participation.
Deﬁnitive identiﬁcation was attained using the API 20E kit
(bioMerieux, Marcy l’Etoile, France) and commercial antisera
(BD Biosciences, Frankland Lakes, NJ, USA). Susceptibility to
antibiotic discs containing ampicillin (10 mg), chlorampheni-
col (30 mg), trimethoprim-sulfamethoxazole (25 mg), cipro-
ﬂoxacin (5 mg), ceftriaxone (30 mg) and nalidixic acid
(30 mg) (Becton-Dickinson, Sparks, MD, USA) was evaluated
using the disc-diffusion method. The E-test (bioMerieux) was
employed to determine the MICs of ciproﬂoxacin only. All
interpretations were made according to CLSI, 2012. MDR
was deﬁned as the simultaneous resistance of bacteria to
chloramphenicol, ampicillin and trimethoprim-sulfamethoxaz-
ole. The sensitivity and speciﬁcity of the nalidixic acid
assay as a surrogate of the ciproﬂoxacin E-test were
calculated. Proportions were compared using the chi-s-
quared test.
Results
A total of 968 S. Typhi isolates from Egypt (n = 654),
Uzbekistan (n = 123), Pakistan (n = 65), Iraq (n = 59), Qatar
(n = 43) and Jordan (n = 24) were used in this study. The
prevalence of MDR S. Typhi isolates was signiﬁcantly higher in
Iraq (49/59, 83%) and Pakistan (34/65, 52%) than in other
countries included in this study (13–17%, p <0.01; Table 1).
Within Egypt, the majority of isolates were from four different
governorates: Fayoum (41%), Cairo (25%), Aswan (10%) and
Alexandria (7%). Fayoum isolates showed a signiﬁcantly higher
MDR prevalence (29%; p <0.05) when compared with the
other governorates (0–7%; p <0.05; Table 2).
Nearly all isolates were susceptible to ceftriaxone, except
for two from Alexandria, Egypt, which showed intermediate
resistance (total susceptibility 99.7%) and were negative for
extended spectrum b-lactamase production. For ciproﬂoxacin,
only 48% were susceptible by the disc-diffusion method, with
zone diameters ≥31 mm (Table 1). The remaining isolates
were either intermediate (47%, 21–30 mm) or fully resistant
(5%, ≤20 mm), with relatively elevated MICs ranging from
0.125 to 0.75 lg/mL (mean 0.33  0.12 lg/mL). Meanwhile,
susceptibility to nalidixic acid by the disc-diffusion method was
74%, 4% were intermediate and 22% were resistant. Isolates
that tested nalidixic acid resistant (n = 218, 22%) correspond-
ingly showed elevated MICs for ciproﬂoxacin in 216 isolates,
ranging from 0.125 to 0.94 lg/mL (average 0.29  0.11 lg/
mL) RSC. The remaining two isolates were susceptible to
ciproﬂoxacin (<0.064 lg/mL). The distribution of RSC
reﬂected a broad geographic variability: Iraq (92%); Uzbekistan
(80%); Qatar (54%); Pakistan (47%); Jordan (8%) and; Egypt
(2%) (Table 1). Use of nalidixic acid resistance as an indicator
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of reduced ciproﬂoxacin susceptibility was 99% sensitive and
99.7% speciﬁc.
Discussion
The high proportions of S. Typhi strains demonstrating MDR
from Iraq (83%) and Pakistan (52%) relative to those from
other countries in this study (≤17%) are consistent with a
recent report indicating that 80% of patients infected with
MDR S. Typhi originate from the Asian continent and the
remainder occur mostly in Africa and Latin America [18].
Self-medication and unguided antibiotic treatment are two
main reasons for MDR development. Since the institution of
ciproﬂoxacin as a preferred treatment choice for MDR
S. Typhi cases, RSC has emerged, ﬁrst in India (69%) in 1996,
Vietnam (76%) in 1997, Tajikistan (the percentage is not clear)
in 1998 and subsequently in other parts of the world, including
the UK, Mexico, Thailand, Korea and Peru [19,20]. In our
study the prevalence of RSC was predictable in Pakistan (47%),
but the particularly high rate (92%) seen in Iraq may indicate a
widespread and/or inappropriate use of ﬂuoroquinolones in
this country. This may concur with the observation that many
isolates tested from this region were obtained during acute
febrile illness outbreaks, which is probably a limitation that
reﬂects the selection of more serious or more resistant
epidemic strains.
Although only 13% of Uzbekistan isolates from this study
were MDR, 80% showed RSC, in agreement with previous
ﬁndings from Samarkand, the second largest city in Uzbe-
kistan [7]. This may indicate that ﬂuoroquinolones have
been used more commonly than other conventional antibi-
otics for the treatment of typhoid fever. In 2003, the
government of Uzbekistan implemented routine immuniza-
tions in speciﬁc areas of the country to reduce typhoid
fever incidence [21].
In Qatar, over one half of the isolates demonstrated RSC
(54%), while only 14% were MDR. This may be attributed to
the importation of S. Typhi strains from the Indian sub-con-
tinent, where it is endemic, and the Far East; it has been
estimated that expatriate workers constitute 30–40% of the
population in the Gulf States [1]. A recent study [22] detected
RSC in 44% of S. Typhi isolates from the Gulf region and
warned against compromising treatments.
In Amman, Jordan, 8% of isolates demonstrated RSC, a
relatively small percentage that is contrary to a recent local
report claiming virtually no resistance to this drug among
S. Typhi isolates between 2004 and 2006 [5]. The discrepancy
in Jordan’s ﬁndings may be attributed to the involvement of
sporadic cases living in the Jordan Valley, about 50 km west of
Amman, disconnecting this area from incoming strains to the
country’s capital through foreign labor.
In Egypt, the rate of RSC among S. Typhi isolates was low
(2%), ranging from 0% in Asiut Governorate (in southern
Egypt), Menofyia (Nile Delta region), Gharbia (3%, Delta) to
4% in Alexandria (on the Mediterranean coast) (Table 2).
Similarly, MDR rates were low except in the Fayoum
Governorate (29%; p <0.05), possibly as the result of poor
sanitation, limited urbanization and unguided use of antibiotics
in this governorate.
Our ﬁndings showed that almost all isolates were suscep-
tible (99.7%) to ceftriaxone (a third-generation cephalosporin),
which remains the drug of choice for the treatment of typhoid
fever [9,10]. However, the unprecedented detection of two
isolates with intermediate resistance to ceftriaxone from
Alexandria, Egypt is an early warning sign indicating the need
for more controlled use of this drug in the country and in the
region. Previously, all S. Typhi isolates from Egypt were
claimed to be susceptible [10,23].
The continued spread of MDR strains and reduced effec-
tiveness of standard drug regimens are serious threats to the
treatment of typhoid fever in endemic countries. Although
ceftriaxone was the most reliable choice for MDR and nalidixic
acid-resistant S. Typhi isolates, a high level resistance to
ceftriaxone (MIC 64 mg/L) has been reported from Bangladesh
in 1999 [24,25]. The two isolates showing intermediate
resistance to ceftriaxone in this study were negative for
extended spectrum b-lactamase production, though reported
in a strain from a 54 year old Dutch man returning from the
Philippines [26].
The observation that nalidixic acid resistance can predict
RSC in antimicrobial disc-diffusion susceptibility testing has
been documented before [14,16]. In this study, the sensitivity
and speciﬁcity of the assay were 99% and 99.7%, respectively.
It relies on a mutation in the gyrA gene and occasionally the
parC gene is included, leading to higher level of resistance
(MICs from 8 to >32 lg/mL) [27,28].
This study used 968 S. Typhi isolates collected from six
countries over 6 years. The obtained data must be interpreted
with care, as isolates may not be necessarily representative of
either geographical coverage or time-frame. However, the
ﬁndings alert the scientiﬁc and medical communities in the
Middle East and Central Asia regions to the emergence of
reduced ﬂuoroquinolone susceptibility. The positive and
negative predictive values of nalidixic acid susceptibility testing
are high (99% and 99.7%, respectively) and present a cheaper
and more practical tool to predict RSC. Consideration should
be given to the use of more conventional drugs (chloramphe-
nicol, ampicillin or trimethoprim-sulfamethoxazole) for the
treatment of typhoid fever in countries with low MDR
ª 2014 The Authors. New Microbes and New Infections published by John Wiley & Sons Ltd on behalf of the European Society of Clinical Microbiology and Infectious Disease., NMNI, 2, 88–92
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prevalence. Also, routine antibiotic susceptibility testing of
isolates should be consistently performed (e.g. nalidixic acid
testing to predict RSC) before prescribing quinolones or
cephalosporins to avoid compromising treatment options.
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